Floatz logo

Tislelizumab

Urothelial Carcinoma

Explore 163 assets in Urothelial Carcinoma →
Floatz Rating
B58/100
Confidence
Indicative
v0.2
Sponsor
Indaptus Therapeutics, Inc
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05651022CT.gov
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
—Active Not Recruiting———
NCT05661955CT.gov
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
—Active Not Recruiting———
NCT04802876CT.gov
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
—Active Not Recruiting———
NCT04666688CT.gov
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Urothelial Carcinoma

AssetSponsorPhaseRating
Tislelizumab (this asset)Indaptus Therapeutics, IncP2B · 58
CyclophosphamideBeijing BiotechP3BB
DurvalumabAlliance for Clinical Trials in OncologyP3BB
Cis-Diamminedichloroplatinum IiNagoya UniversityP3BB
PembrolizumabSutro Biopharma, Inc.P3BB
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Vasgene Therapeutics, IncP2/3BB
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, DimerEli Lilly and CompanyP3BB
RetifanlimabIncyte CorporationP2BB
DocetaxelNuCana plcP3BB

+42 more in the Urothelial Carcinoma cohort

Other indications for Tislelizumab

IndicationSponsorPhaseRating
Non-Small Cell Lung Carcinoma—P4BB · 69
Diffuse Large B-Cell Lymphoma—P3BB · 67
Classic Hodgkin Lymphoma—P3BB · 67

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Tislelizumab in Urothelial Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/tislelizumab-urothelial-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →